Steroid hormones and cancer: IV Prostate cancer

European Journal of Surgical Oncology

Volumn 23, Issue 3, 1997, Pages 264-268

  Habib, F K ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

5 reductase; Androgen receptor; Genes; Mutations; Tri nucleotide repeat

Indexed keywords

ANDROGEN; STEROID HORMONE;

CANCER INCIDENCE; CANCER RISK; ETHNIC DIFFERENCE; HUMAN; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; SHORT SURVEY;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANDROGENS; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0030760874     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(97)92604-4     Document Type: Article

References (36)

1. Alexander F, Boyle P. The rise in prostalic cancer: myth or reality? In: Garraway M (ed.) Epidemiology of Prostate Disease. Berlin: Springer-Verlag. 1995: 192-201.
2. Carter HP, Coffey DS. The prostate: an increasing medical problem. Prostate 1990; 16: 187-97.
3. Muir C, Waterhouse J. Mack T, Powell J, Whelan S (eds) Cancer Incidence in 5 Continents, Vol. 5. Lyon: IARC Press, 1987.
4. Pienta KJ, Esper PS. Risk factors in prostate cancer. Ann Int Med 1993; 118: 793-803.
5. Lipsett MB. Interaction of drugs, hormones and nutrition in the causes of cancer. Cancer 1979; 43: 1967-81.
6. Robson MC. Cirrhosis and prostatic neoplasms. Geriatrics 1966; 21: 150-4.
7. Drafta D, Proca E, Zamfir V, Schindler AE, Neacsu E, Stroe E. Plasma steriods in benign prostatic hypertrophy and carcincoma of the prostate. J Steriod Biochem 1982; 17: 689-93.
8. Bartsch W, Steins P, Becker H. Hormone blood levels in patients with prostatic carcinoma and their relation to the type of carcinoma growth differentiation. Eur Urol 1977; 3: 47-52.
9. Habib FK, Lee IR, Stitch SR, Smith PH. Androgen levels in the plasma and prostatic tissues of patients with benign hypertrophy and carcinoma of the prostate. J Endocrinol 1976; 71: 99-107.
10. Bartsch W, Horst HJ, Becker H, Nehse G. Sex hormone binding globulin binding capacity, testosterone, 5α-dihydrolestosterone, oestradiol and prolactin in plasma of patients with prostate carcinoma on their various types of hormonal treatment. Acta Endocrinol 1977; 85: 650-64.
11. Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL. A prospective based study of androstenedione, oestrogens and prostate cancer. Cancer Res 1990; 50: 169-73.
12. Lookingbill DP, Demers LM, Wang C, Leung A, Rittmastar RS, Santen RJ. Clinical and biochemical parameters of androgen action in normal healthy caucasian versus Chinese subjects. J Clin Endocrinol Metab 1991; 72: 1242-8.
13. DeJong FH, Oishi K, Hays RB, et al. Peripheral hormone levels in controls and patients with prostate cancer or benign prostatic hyperplasia: Results from the Dutch-Japanese Case-Control Study. Cancer Res 1991; 51: 3445-50.
14. Ross RK, Coetzee GA, Reichardtt J, Skinner E, Henderson BE. Does the racial/ethnic variation in prostate cancer risk have an hormonal basis. Cancer 1995; 75: 1778-82.
15. Blackard CE, Byar DP, Jordan WP, for the Veterans Administration Co-operative Urological Research Group. Orchiectomy for advanced carcinoma: a re-evaluation. Urology 1973; 1: 533-60.
16. Hsing AW, Comstock GW. Serological precursors of cancer: Serum hormones and risk of subsequent prostate cancer. Cancer Epid Bio Mark Prev 1993; 2: 27-32.
17. Habib FK, Goodman CM, Buck AC. Androgen concentrations in expressed prostatic secretions: No correlation with tissue levels. Urol Res 1992; 20: 281-4.
18. α-reduclase activity and androgen receptor content. J Clin Endocrinol Metab 1989; 68: 461-8.
19. Geller J, Albert J. Loza D, Geller S, Stoeltzing W, Delavega D. DHT concentrations in human prostate cancer tissue. J Clin Endocrinol Metab 1978; 46: 440-4.
20. Habib FK. Prostate mechanisms of normal and abnormal metabolism. In: Chisholm GD, Fair WR (eds) Scientific Foundations of Urology (3rd edn). London: Wm Heinemann Medical Book's 1990; 358-65.
21. Imperato-McGinley J, Gautier T, Zirinsky K, et al. Visualisation studies in males homozygous and heterozygous for 5α-reductase deficiency. J Clin Endocrinol Metab 1992; 75: 1022-6.
22. Hudson RW, Wherrett D. Comparison of nuclear 5α-reduction of testosterone and androstenedione in human prostatic carcinoma and benign prostatic hyperplasia. J Steriod Biochem 1990; 35: 231-6.
23. Habib FK, Busuttil A, Robinson RA, Chisholm GD. 5α-reductase activity in human prostate cancer is related to the histological differentiation of the tumour. Clin Endocrinol 1985; 23:431-8.
24. Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human steriod 5α-reductase. Proc Natl Acad Sci USA 1990: 87: 3640-4.
25. Jenkins EP, Andersson S, Imperato-McGinley J, Wilson JD, Russell DW. Genetic and pharmacological evidence for more than one human steriod 5α-reductase. J Clin Invest 1992; 89: 293-300.
26. Habib FK, Ross M, Tate R, Chisholm GD. Differential effect offinasteride on the androgen concentrations in benign tissular hyperplasia. Clin Endocrinol 1997: 46:
27. Beato M. Gene regulation by steroid hormones. Cell 1989; 56: 335-44.
28. Riegman PHJ, Vlietstra RJ, Corput JAGM. Van der Brinkmann AO, Trapmann J. The promoter of the prostate specific antigen contains a functional androgen responsive element. Mol Endocrinol 1991; 5: 1921-30.
29. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Distant metastasis from prostatic carcinoma express androgen receptor protein. Cancer Res 1995; 14: 3068-72.
30. Van der Kwast TH, Schalken J, Ruizeveld DE, et al. Androgen receptors in endocrine therapy resistant to human prostate cancer. Int J Cancer 1991; 48: 189-93.
31. Sadi MV, Barrack AR. Image analysis of androgen receptor immunostaining in metastatic prostate cancer heterogeneity as a predictor of response to hormonal therapy. Cancer 1993; 71: 2574-80.
32. Culig Z, Hobisch A, Croneuer MV, et al. Mutant androgen receptor detecting an advanced stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993; 7: 1541-50.
33. Newmark JR, Hardy EO, Tomb DC, el al. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 1992; 89: 6319-23.
34. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S. Frequent detection of cordon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 1994; 54: 2861-4.
35. Visakorpi T, Hyytine E, Kkoivisto P, et al. Amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics 1995; 9: 401-6.
36. Irvine RA, Yu MC, Ross RK, Coetzee GA. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995; 55: 1937-40.